One of the largest pharmaceutical companies in the world is expanding.
American company Merck is buying Cubist Pharmaceuticals for $8.4 billion.
Cubist specializes in advanced antibiotic research, so for Merck the deal highlights an emphasis on fighting "superbugs" that multiple global health organizations have continuously warned about, according to The Associated Press.
In April, the World Health organization announced that unless a strong effort is put in place, "the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill."
The deal will add more than $1 billion of revenue to Merck in 2015 and includes $1.1 billion in debt. Merck expects to profit even more from the deal in the future.
Merck will pay $102 per share of Cubist to help its entry into the market.
